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BY-NC-ND license (http://creativecomBackground: The majority of nontyphoid Salmonella infection is identified in children. When
an invasive or severe Salmonella infection is encountered, ceftriaxone is recommended for
such patients. A 2-year-old girl was hospitalized for the treatment of Salmonella bacteremia
and discharged with standard ceftriaxone treatment. She was readmitted to the hospital after
2 days due to the recurrence of the Salmonella bacteremia. The study aimed to unveil the
mechanism for the relapse.
Methods: Six isolates (4 blood and 2 stool) were recovered from the patient, with the last two
blood isolates being ceftriaxone-resistant. Pulsed-field gel electrophoresis was used for geno-
typing. Ceftriaxone resistance genes and transferability of the resistance plasmid were exam-
ined by molecular methods.
Results: All isolates were identified as Salmonella enterica serotype Oranienburg. Five isolates
demonstrated almost identical electrophoresis patterns, except that in the two ceftriaxone-
resistant isolates an extra band (>100 kb) was noted. A blaCMY-2 gene, carried by a 120-kbof Medical Biotechnology and Laboratory Science, Chang Gung University College of Medicine, 259,
aoyuan, Taiwan.
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42 W.-C. Yang et al.conjugative IncI1 plasmid of the sequence type 53, was identified in the two ceftriaxone-
resistant isolates. Transfer of the resistance plasmid from one blood isolate to Escherichia coli
J53 resulted in the increase of ceftriaxone minimum inhibitory concentration from 0.125 mg/
mL to 32 mg/mL in the recipient.
Conclusion: Ceftriaxone is the standard therapeutic choice for invasive or serious Salmonella
infections in children. Pediatricians should be aware of the possibility of resistance develop-
ment during therapy, especially in areas with a widespread of ceftriaxone resistance genes
that are carried by a self-transferrable plasmid, such as the blaCMY-2-carrying IncI1 plasmid
identified herein.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Salmonella infection is an important public health problem
worldwide, and children younger than 5 years constitute
the largest population among patients with Salmonella
infection in both developed or developing countries.1,2
Nontyphoid Salmonella cause self-limited gastroenteritidis
as well as systemic infections that require antibiotic
treatment.1,3 Appropriate antimicrobial options may
include ampicillin, chloramphenicol, trimetho-
primesulfamethoxazole, fluoroquinolones, or expanded-
spectrum cephalosporins (ESCs).1,4 However, resistance of
Salmonella to conventional antibiotics has been high in
recent years, leaving fluoroquinolones and ESCs as the only
effective agents against nontyphoid Salmonella infection.5
However, resistance to ESCs among Salmonella has been
noted since the late 1980s.4 Spread of plasmid-mediated
AmpC or extended-spectrum b-lactamase genes further
lead to the increase of ceftriaxone resistance in nontyphoid
Salmonella.4 Because fluoroquinolones are generally not
recommended in children,6 ceftriaxone resistance in pedi-
atric Salmonella infection therefore represents a serious
clinical problem. Here, we report a case of relapse
bacteremia caused by Salmonella enterica serotype Ora-
nienburg. Laboratory investigation revealed that ceftriax-
one resistance developed in the Salmonella during therapy,
leading to the relapse of bacteremia caused by the same
strain.Materials and methods
The patient
On September 1, 2011, a 2-year-old girl presented to the
outpatient department with a 1-week history of intermit-
tent fever, fatigue, diarrhea, and abdominal pain. She had
received regular vaccination and did not have any signifi-
cant diseases in the past. The physical examination was
otherwise unremarkable except that she appeared mildly
dehydrated. Laboratory studies revealed a leukocyte count
of 7.2  109 cells/L with 52% neutrophils; hematocrit,
34.4%; platelet count, 212  109/L; and elevated C-reactive
protein, 135.81 mg/L. She was hospitalized on the same day
and her blood, urine, and stool were collected for bacterial
culture.On admission, her temperature was 39.4C, pulse rate
122 beats/minute, respiratory rate 26 breaths/minute, and
blood pressure 118/43 mmHg. The patient was fluid resus-
citated and started to receive intravenous ampicillin
(100 mg/kg/day). The blood culture yielded Gram-negative
bacilli on the next day, and the antibiotic was shifted to
ceftriaxone. Both blood and stool cultures grew
ceftriaxone-susceptible S. enterica serogroup C1 (SC834
and SC773, respectively). A second blood culture drawn on
Day 3 still yielded the same organism (SC835).
The patient’s fever subsided on Day 4. Ceftriaxone was
applied for 5 days and then shifted to oral antibiotic ther-
apy with cefixime (8 mg/kg/day). A third blood culture was
drawn on Day 6. The patient was discharged on Day 9 with
an apparently well condition, despite a preliminary labo-
ratory report indicating the growth of S. enterica serogroup
C1 (SC836) from the third blood culture. For follow-up, a
fourth blood culture, later grew S. enterica serogroup C1
(SC837), was drawn just prior to the patient’s discharge.
Both SC836 and SC837 were subsequently reported to be
resistant to ceftriaxone.
Two days later, the patient presented to the emergency
department with an intermittent fever for 1 day. Labora-
tory studies at the time revealed a leukocyte count of
6.4  109/L with 66% neutrophils; hematocrit, 35.2%;
platelet count, 290  109/L; and C-reactive protein,
17.17 mg/L. A fifth blood culture was drawn but later found
to be sterile. Because the blood culture taken prior to the
discharge of the first hospitalization grew ceftriaxone-
resistant S. enterica serogroup C1, intravenous imipenem
(80 mg/kg/day) was prescribed. A gallium-67 scan was ar-
ranged and showed negative findings. The fever subsided on
the next day. Imipenem was used for 6 days and the patient
was discharged without any sequelae.
Bacteria and antimicrobial susceptibility
A total of six isolates, four from blood and two from stool
cultures, of S. enterica serogroup C1 were identified from
the patient with standard methods (Table 1). Serogroups
and serotypes of the isolates were analyzed with O and H
antisera using standard methods. Antimicrobial suscepti-
bility of the isolates was examined by a standard disk
diffusion method, and minimum inhibitory concentrations
(MICs) of ceftriaxone were assessed with E-test strips (AB
Biodisk, Solna, Sweden). The results were interpreted
Table 1 Laboratory characterization of the six Salmonella enterica serotype Oranienburg isolates
Isolate Specimen Antimicrobial susceptibility MICCRO
(mg/mL)
bla gene Plasmid
profile (kb)AMP CHL SXT CIP CFM CRO ETP IPM
Salmonella
Oranienburg
SC834 Blood S S S S S S S S 0.064 d d
SC773 Stool S S S S S S S S 0.032 d 120,190
SC773B Stool S S S S S S S S 0.125 d d
SC835 Blood S S S S S S S S 0.064 d d
SC836 Blood R R S S R R S S 32 CMY-2 120a
SC837 Blood R R S S R R S S 32 CMY-2 120a
Escherichia coli
J53 S S S S S S S S 0.125 d d
J53/pSC837 R R S S R R S S 32 CMY-2 120a
a blaCMY-2-carrying IncI1 plasmid.
AMZ ampicillin; CZ chloramphenicol; CFMZ cefixime; CIPZ ciprofloxacin; CROZ ceftriaxone; ETPZ ertapenem; IPMZ imipenem;
SXT Z sulfamethoxazoleetrimethoprim.
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Standards Institute.7
Ceftriaxone resistance mechanisms and genetic
relatedness of the isolates
Genetic relatedness of the isolates was investigated by
pulsed-field gel electrophoresis (PFGE) and interpreted as
described earlier.8 Ceftriaxone resistance was investigated
by using polymerase chain reaction and sequencing as re-
ported previously.9 Plasmid profiles of the isolates were
analyzed by an alkaline lysis method.10 DNAeDNA hybridi-
zation was used to locate the resistance genes.11 Conju-
gation experiments using azide-resistant Escherichia coli
J53 as the recipient were performed with a filter mating
method.12 Replicon typing and plasmid multilocus sequence
typing were used to characterize the resistance plasmids
with published methods.13,14
Results
The six isolates of S. enterica serogroup C1 were all
confirmed to be S. enterica serotype Oranienburg. Five of
the isolates were found to have almost identical PFGE
patterns, with a minor difference demonstrated by an extra
band of slightly larger than 100 kb in SC836 and SC837
(Fig. 1A, upper panel, arrowhead). SC773 was the only
isolate showing a completely different PFGE pattern
(Fig. 1A, upper panel). Actually, SC773 and SC773B were
both isolated from the only stool specimen subjected for
microbial culture examination. During the preliminary PFGE
analysis, SC773 was found to have a different PFGE pattern
compared to those demonstrated by the other blood iso-
lates. SC773B was subsequently identified with an extra
effort trying to find other isolates from the original stool
culture media that may have the same PFGE patterns as
those of the blood isolates.
A blaCMY-2 gene was identified in SC836 and SC837, the
last two blood isolates that showed ceftriaxone resistance.
No other genes for extended-spectrum b-lactamases orplasmid-mediated AmpCs were further identified. Plasmid
profile analysis also revealed an additional 120-kb plasmid
in SC836 and SC837 (Table 1; Fig. 1B, upper panel). The
blaCMY-2 gene was found to be carried by this plasmid, which
was later proved to be a self-transferrable IncI1 plasmid
with a sequence type 53 (Fig. 1B, lower panels). The extra
band identified by PFGE analysis in SC836 and SC837 was
also due to the additional blaCMY-2-carrying IncI1 plasmid as
revealed by DNAeDNA hybridization (Fig. 1A, lower panel).
Transfer of the blaCMY-2-carrying IncI1 plasmid from SC837
to E. coli J53 resulted in the increase of ceftriaxone MICs
from 0.125 mg/mL to 32 mg/mL in the recipient (Table 1).Discussion
The standard therapeutic choice for serious Salmonella
infections in children is ceftriaxone. In the present study,
standard antimicrobial therapy had been given and the
clinical presentation had been improved when the patient
was allowed to be discharged during the first hospitaliza-
tion. Unfortunately, the patient had to be re-admit to the
hospital due to a relapse of the infection. Recurrent inva-
sive nontyphoid Salmonella infection is common among
immunocompromised patients, despite appropriate anti-
microbial therapy.15,16 Our patient does not have other
significant disease history, nor did the image study reveal
any focal infection. The young age, which includes her in
the most susceptible population for suffering from Salmo-
nella infection,1 may be one of the key host factors leading
to the relapse of the infection by the same organism while
with additional ceftriaxone resistance. However, although
the change in the ceftriaxone susceptibility had not been
finally reported at the discharge of the patient, a pre-
liminary report did show that there were remaining Sal-
monella organisms in the patient’s blood. This might be a
strong hint that the patient should stay for a longer period
in hospital until all the bacteria have been cleared. The
case also suggests that for an invasive Salmonella infection,
particularly in young children, eradication of the infection
as evidenced by microbial culture results may be one of the
Figure 1. (A) Pulsed-field gel electrophoresis patterns and (B) plasmid profiles of the isolates studied. DNA-DNA hybridization
results are shown in the corresponding lower panel. Hybridization with CMY-2 or IncI1 probes demonstrated the same results. MZ l
DNA concatemer standard (A) or plasmid size markers (B); Lanes 1e6, Salmonella enterica serotype Oranienburg SC834, SC773B,
SC773, SC835, SC836, and SC837; Lanes 7 and 8, Escherichia coli J53/pSC837, and E. coli J53 (B). The extra band presented in SC836
and SC837 is indicated by the arrowhead (A).
44 W.-C. Yang et al.most important prerequisite factors, other than the
remission of clinical symptoms and signs, to discharge the
patient.
Recurrence of invasive nontyphoid Salmonella infection
after antimicrobial treatment may be due to a relapse
infection with the same organism that developed antimi-
crobial resistance during therapy, and/or reinfection with a
different strain that had been resistant to the antibiotics
used.15 Recurrence of Salmonella infection after cipro-
floxacin or ceftriaxone treatment has been reported.17,18
With PFGE analysis, we were able to show that the sec-
ondary infection was actually a relapse infection of the
prior bacteremia. By acquiring the blaCMY-2-carrying IncI1
plasmid, the organism became resistant to both ceftriaxone
and cefixime. Fortunately, the patient readmitted to this
hospital, with the documentation of previous culture re-
sults, the antimicrobial agent was changed to imipenem,
and the illness was soon controlled. The successful treat-
ment of the relapse infection with imipenem provides
further evidence that carbapenems can be used for the
treatment of severe Salmonella infection with ceftriaxone
resistance, especially in children or when the causative
agent also demonstrated ciprofloxacin resistance.18 How-
ever, development of carbapenem resistance during ther-
apy for nontyphoid Salmonella infection has beenreported.19 Physicians are advised to use with caution and
follow-up microbial examinations are necessary to monitor
the therapeutic effect.
Infection caused by S. enterica serotype Oranienburg
can progress to become severe infections, including sepsis,
and the subsequent focal infections such as aneurysm,
cholecystitis, osteomyelitis, and abscesses in various organs
or tissues.20e25 Timely use of appropriate antimicrobial
therapy is therefore required for a satisfactory recovery.
However, resistance to the antimicrobial agent used could
occur during therapy as described herein. Ceftriaxone
resistance in S. enterica serotype Oranienburg has been
linked to the production of CTX-M-2, CTX-M-3, and CTX-M-
14.26e28 In the present study, the acquisition of the blaCMY-
2-carrying IncI1 plasmid in the S. enterica serotype Ora-
nienburg appears to be the major reason for the ceftriax-
one resistance, leading to the subsequent relapse infection
in the patient.
Previously we have demonstrated the prevalence of the
blaCMY-2-carrying IncI1 plasmid among several Salmonella
serotypes that belonged to the serogroups B and D.29 In the
present report, the resistance plasmid was found to have
been transmitted into a serogroup C serotype, Oranienburg.
Compared to adult patients, children appear to be more
vulnerable to nontyphoid Salmonella infection.1 Although
Ceftriaxone-resistant Salmonella Oranienburg 45ceftriaxone is the most frequently used antimicrobial agent
in treating pediatric patients with invasive or severe Sal-
monella infection, cautions should be taken regarding the
possibility of resistance development during therapy. It is
especially important in areas with a widespread of ceftri-
axone resistance genes that are carried by self-
transferrable plasmids, such as the blaCMY-2-carrying IncI1
plasmid identified herein.
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